Adicet Bio, Inc. ACET
Adicet Bio, Inc. (Nasdaq: ACET) is an immunology/inflammation drug developer. Its lead program, prula-cel, is in Phase 1 for systemic lupus erythematosus (SLE), including lupus nephritis (LN) and extra-renal SLE. Its next catalyst on record is prula-cel (SLE): FDA engagement regarding potential expansion of pivotal development program to include lupus patients without nephritis (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: prula-cel (SLE) — FDA engagement regarding potential expansion of pivotal development program to include lupus patients without nephritis (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| prula-cel | systemic lupus erythematosus (SLE), lupus nephritis (LN), extra-renal SLE | cell therapy | Phase 1 |
| prula-cel | systemic sclerosis (SSc) | cell therapy | Phase 1 |
| prula-cel | anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) | cell therapy | Phase 1 |
| prula-cel | idiopathic inflammatory myopathies (IIM) | cell therapy | Phase 1 |
| prula-cel | stiff person syndrome (SPS) | cell therapy | Phase 1 |
| ADI-212 | metastatic castration-resistant prostate cancer (mCRPC) | cell therapy | Phase 1 |
| In vivo CAR-T program | multiple myeloma, non-Hodgkin's lymphoma (NHL), solid tumors | gene therapy | Pre-clinical |
Recent results and decisions
- Nov 5, 2026started Pivotal LN study startup activities are underway for prula-cel.
The Company has initiated start-up activities for a pivotal study in LN.
Filing - Sep 28, 2026positive Phase 1 prula-cel in SLE/LN (22 evaluable): at 12 months 50% of LN patients had complete renal response and 54% achieved DORIS remission, no CRS above Grade 2, no ICANS or IEC-HS.
At the 12-month mark, 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission.
Filing - Sep 1, 2026positive Prula-cel demonstrated positive safety and efficacy in Phase 1 trial of SLE with or without LN, with 50% complete renal response at 12 months in LN patients.
Prula-cel continued to demonstrate positive clinical responses and a favorable safety profile in this heavily pretreated population.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.